PREDICTIVE ONCOLOGY :
Our Companies

Helomics

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. 

Visit Helomics.com

15+

Years of outcome data

137

Tumor types

View products and solutions now at
Helomics

Let us tell you about Helomics.

Helomics has a key proprietary technology platform and data pipeline that provides next-generation, AI- and data-driven services to Pharma and Diagnostic companies to accelerate the development of new precision therapies.

For BioPharma, Helomics improves the efficiency and cost effectiveness
of the discovery of new drugs. For Clinicians, Helomics helps oncologists to individualize current therapies for patients.

Helomics uses artificial intelligence (AI) to improve the accuracy, predictability and speed of BioPharma R&D. With AI, Helomics can:

  • Reduce the timeframe and increase the agility 
    of the drug discovery process

  • Raise the accuracy of efficacy and safety of drugs

  • Improve the diversity of the drug portfolio against a given cancer

Helomics owns the world’s largest patient tumor drug response and genomic knowledge base gained from testing of 150K+ clinical cases covering 137 tumor types in our unique clinically validated PDx platform.

We have advanced AI software. Our CoRE™ (Computational Research Engine) is a comprehensive in silico platform that iteratively optimizes predictive models using guided selection of experiments, developed by top researchers at Carnegie Mellon University. CoRE employs a polypharmacological/pharmacogenomic approach which builds a large set of predictive models and selects the optimal pairing of data and algorithm using a comprehensive machine learning methodology. We maintain active clinical testing in our CLIA certified lab.

Clinical
Testing


Helomics helps to personalize patient therapies

Drug
Discovery


Helomics database of 150K+ tumors aids in reducing discovery timeline

Oncology
Research


TumorGenesis develops living tumors outside the body for study and testing

Drug
Development


Soluble Biotech supplies formulations for delivery of therapeutics and vaccines

Cell
Cultures


zPREDICTA utilizes tumor-specific 3D cell culture models, enabling more successful drug development

What problems do we solve?

Shortens time to clinical trials and lowers development costs

Critical upstream function improves discovery results

AI platform saves money and time needed to push therapies to clinical trials

CLIA-regulated functional test profiles treatment options on patient’s own living tumor to guide oncologist therapy choices

What are our major offerings?

Introducing the TruTumor Platform​

TruTumor is a proprietary clinically validated* primary tumor cell culture assay that has proven clinical utility as a predictive and prognostic drug response marker.


View Product

 

Biorepository Services​

Helomics offers a full range of biorepository services for Pharma, BioPharma and Diagnostic companies, to address the needs for specimen lifecycle management from transport, through storage to processing and destruction.


View Product

 

CoRE Active Learning​

CoRE- (Computational Research Engine)
is a comprehensive in silico platform that Iteratively optimizes predictive models using guided selection of experiments.


View Product

 

LET’S WORK TOGETHER

Helomics corporate contacts:

Product Development/R&D

Richard Gabriel
Email
781-883-6639

Operations/Site Leader/Medical Director

Arlette Uihlein, MD
Email
412-432-1500

Julia Kirshner, Ph.D.

PRESIDENT,
zPREDICTA

Dr. Kirshner has over 15 years of experience in cancer research, including preclinical model design, drug discovery and efficacy testing. Dr. Kirshner’s expertise spans multiple aspects of cancer biology including the development of physiological organotypic 3D cell culture models for preclinical drug testing, molecular target and biomarker discovery, evaluation of drug-resistance, tumor microenvironment, tumor heterogeneity and cancer stem cells, and tumor immunology. 

At Predictive Oncology

As the founder of zPREDICTA, Dr. Kirshner leads the team in developing tumor-specific in vitro models for oncology drug discovery and research. The company is focused on accelerating the drug development process through its expertise in carcinogenesis, metastasis, and the tumor microenvironment. zPREDICTA’s complex in vitro models recapitulate the physiological environment of human cancer tissue and thus provide a more clinically relevant testing platform than commonly used alternatives.

Before Predictive Oncology

Prior to starting zPREDICTA, Dr. Kirshner was an Assistant Professor of Biological Sciences at Purdue University.  

“ Combining zPREDICTA’s technology with Helomics, TumorGenesis, and Soluble Biotech will allow us to make true progress towards our joint mission of eliminating cancer.”

Education
Irell & Manella Graduate School of Biological Sciences

Ph.D., Molecular and Cell Biology

University of California, Davis
B.S., Genetics

Pamela Bush, Ph.D.

SVP, Strategic Sales and Business Development,

PREDICTIVE ONCOLOGY
At Predictive Oncology

Pamela Bush comes with more than twenty years of experience in venture creation, finance, and business development in the life sciences industry. At POAI, she leads the sales efforts and business development activities across the portfolio.

Before Predictive Oncology

Prior to joining POAI Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 80+ life sciences start-ups.

“ POAI has developed solutions to help biopharma partners increase the probability of success of their oncology pipeline.”

Education
Carnegie Mellon University

Ph.D., Molecular Biology
MBA, Tepper School of Business

Lawrence J. DeLucas, Ph.D

SVP, OPERATIONS,
Predictive Oncology
President, Soluble Biotech
At Predictive Oncology

Dr. DeLucas is the Vice president of Operations for Predictive Oncology and President and co-founder of Soluble Biotech, Inc. DeLucas is currently working to complete development of GMP facilities at Soluble Biotech and at TumorGenesis. In addition, he oversees Soluble Biotech’s solubility and stability contracts for numerous pharmaceutical/biotech companies.

Before Predictive Oncology

From 1981-2016 Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology. Dr. DeLucas received five degrees from UAB culminating in a Doctor of Optometry degree and a Ph.D. degree in Biochemistry. He also received honorary Doctor of Science degrees from The Ohio State University, Ferris State University, the State University of New York (SUNY), and the Illinois College of Optometry. He has published 164 peer-reviewed research articles in various scientific journals, co-authored and edited several books on protein crystal growth and membrane proteins and is a co-inventor on 43 patents involving protein crystal growth, novel biotechnologies and structure-based drug design. DeLucas was a payload specialist NASA astronaut and member of the 7-person crew of Space Shuttle Columbia for Mission “STS-50”, called the United States Microgravity Laboratory-1 (USML-1) Spacelab mission. Columbia launched on June 25, 1992, returning on July 9.  In 1994 and 1995, Dr. DeLucas served as the Chief Scientist for the International Space Station at NASA Headquarters in Washington, D.C. In 1999, Dr. DeLucas was recognized as one of the scientists who could shape the 21st century in an article published by “The Sunday Times” of London titled “The Brains Behind the 21st Century.”  In 2004, he was recognized as a Top Ten Finalist for the Entrepreneur of the Year award from the Birmingham Business Journal. 

“ Soluble Biotech is continually demonstrating to pharmaceutical and biotech companies the significant value of its novel HSC technology for optimizing protein therapeutic formulations to treat a variety of chronic and infectious diseases. ”

Education
  • Five degrees from Univ. of Alabama at Birmingham (UAB): B.S. Chemistry, M.S. Chemistry, B.S. Physiological Optics, O.D. Optometry, Ph.D Biochemistry
    •  
  • Published 164 peer-reviewed research articles in various scientific journals
    •  
  • 1993-2016: Director of the UAB Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology
    •  
  • NASA Astronaut, flew on Columbia Space Shuttle
    •  
  • 1994-1995: Appointed Chief Scientist for the International Space Station at NASA HQ

Arlette Uihlein, MD, FCAP, FASCP

Dr. Arlette Uihlein is Senior Vice President of Regulatory Affairs and Quality for Predictive Oncology and Site Leader of Helomics, serving as the Vice President of Operations, Pathology Services and Medical Director of Helomics® Clinical and Research Labs since 2011. Dr. Uihlein is Board Certified in Anatomic and Clinical Pathology, Cytopathology and Family Medicine. Dr. Uihlein completed her Pathology Residency at Allegheny General Hospital, where she served as Chief Resident in Pathology and completed Fellowships in Cytopathology and Surgical Pathology. During that time, she conducted extensive clinical research involving molecular pathology diagnostic and predictive markers, imaging of solid tumors, and novel applications of cellular tumor markers. While serving as Medical Director at Helomics, a CLIA and New York State certified lab, Dr. Uihlein has published research in molecular assay development, lab automation, and tissue and cell processing. She is a Designated Civil Surgeon for the U.S. Dept. of Justice and a certified Medical Review Officer for the Department of Transportation. She is a Fellow of the College of American Pathologists and the American Society of Clinical Pathology, NYSDOH Certificate Qualified, and a member of ASCO.

“ At Helomics we’re delivering better-informed decision making saving pharma time and money, while providing cancer patients with appropriate therapies.”

 

 

Education

Medical College of Ohio
Doctor of Medicine

Baldwin-Wallace University
BS, Biology

Richard Gabriel, BS, MBA

SVP, RESEARCH & DEVELOPMENT
Predictive Oncology
Site Leader, TumorGenesis
At Predictive Oncology
My role at Predictive Oncology is to bring the business sense to managing Research and Development programs at all our companies. To seek new ways and opportunities to commercialize exciting new technologies that we have built, licensed, acquired, or are developing through our own research and development. The success of any company is to get the research off the bench and to the customers. That is what I do at POAI and help the other companies as well.
Before Predictive Oncology
Prior to starting his first company in 1984 and registering with the FDA a pilot plant facility to make pharmaceutical actives, Mr. Gabriel managed a $50 million product line for W.R. Grace, developed new marketing and sales strategies for Ventron a Division of Morton Thiokol, research work at Ashland Chemical for pressure sensitive adhesives and plant scale-up. Since then, he ran a genetics company, built three GMP/Research facilities, and helped 5 drugs reach their markets in AIDS and cancer. Real expertise in cGMP process scale-up and compliance. Completely understand the needs of an API manufacturing facility and build processes that are scalable, environmentally acceptable, and safe. 3 FDA inspections with no 483’s, ISO certification, DEA registration, DoD compliance, NCI contractor and inventor. Has also broad-based experience in start-up companies and how to make them operational and profitable. 7 years of Team set-up, R&D management, and implementation for 165-person (85 PhD’s and Engineers) company (Pharm-Eco) and lecturer on cGMP and Teams within the Pharmaceutical Industry.

“ Patients are always first, is our driving force. Oncology is a tough space, and we are determined to bring the best validated science to help cancer patients and as our CEO says, ‘Eliminate Cancer.’ That takes teamwork and a lot of smart hard-working people, our team members at POAI are up to the challenge. ”

 

 

Education
Suffolk University
Executive MBA Program

Ohio Dominican College
BS, Chemistry

Ohio State University
Microbiology and Virology

University of Cincinnati
Associates Degree, Liberal Arts

Mark A Collins, Ph.D

SCIENTIFIC/CUSTOMER DEVELOPMENT
Predictive Oncology
Chief Technical Officer, Helomics
At Predictive Oncology

Mark is currently Chief Technical Officer at Predictive Oncology. Using the power of AI, Mark is responsible for leveraging Helomics’ vast repository of physical and digital tumor samples, to build multi-omic predictive models of tumor drug response and outcome. Such models can be applied to the discovery of new targeted therapies for cancer as well as used in clinical decision support to help oncologists individualize  treatment.

Before Predictive Oncology

Dr. Mark Collins embarked on a career in the pharmaceutical industry following his postdoctoral work. Pursuing a passion for both biology and computing, Mark has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the artificial intelligence (AI) machine learning (ML) and drug discovery space. Mark relocated to the USA in 2001 to work for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content cell analysis market, building, and commercializing several key informatics and bioinformatics products.

Since leaving Thermo Fisher, Mark has focused on developing and commercializing informatics solutions for clinical and translational research, specifically in the specimen tracking, ‘omics data management and NGS analysis space, through key roles at BioFortis, Global Specimen Solutions and Genedata

“ I have been pursuing a vision since the late 1990s that AI will help deliver better patient therapies. I firmly believe at POAI we will deliver on that vision. ”

Education
University of Surrey, UK
Ph.D., Microbiology

University of Wolverhampton, UK
Undergraduate Degree, Applied Science

Bob Myers, BBA, MBA

CHIEF FINANCIAL OFFICER
Predictive Oncology
Site Leader, Skyline Medical
At Predictive Oncology

Executive Officer, Compliance Officer, Corporate Secretary, and member of the Senior Leadership Team. Responsible for Finance, Administration, Human Resources, Investor Relations, and IT. Skyline Medical Site Leader.

Before Predictive Oncology

Numerous years as CEO/Controller consultant including medical devices companies. Executive positions with CES Computer Solutions, Computer Accomplishments, Hi-Tech Stationary & Printing, Capital Distributors Corp, International Creative Management American Express, Showtime Entertainment and public accounting with Laventhol & Horwath, CPA’s.

“ It’s a privilege to work with a highly talented team to pursue oncology advances, while protecting and increasing shareholder value. ”

Education

Adelphi University
MBA, Finance

Hofstra University
BBA, Public Accounting 

J. Melville (“Mel”) Engle, BS, MBA

CHIEF EXECUTIVE OFFICER
& CHAIRMAN OF THE BOARD
Predictive Oncology
At Predictive Oncology
Mr. Engle became POAI’s CEO in 2021 and was appointed to the POAI Board of Directors in 2016. He was elected Chairman of the Board in 2020.
Before Predictive Oncology

Between 2012 and 2021, he was CEO of Engle Strategic Solutions, a consulting and coaching company focused on CEO issues. From 2009 to 2012, he was CEO and Chairman of Thermogenesis, a cell separation company. From 2002 to 2007, he was Regional Head/Director, North America at Merck Generics and CEO of Dey Laboratories, a respiratory company. From 1996 to 2001, he was CEO and Chairman of Anika Therapeutics, an orthobiologics company. From 1980 to 1995, he was with Allergan, Inc., an eye and skin care company, where he served as CFO, Managing Director (living in Toronto), and other positions with the firm.

“ Eliminating cancer is our overall goal.  This is not an easy task.  We are working hard every day to make this happen, using our novel technology and talented team of employees. ”

Education

University of Southern California
School of Business
MBA, Finance

University of Colorado Boulder
BS, Accounting